Servier to Acquire Shire's Oncology Business for $2.4B

Shire said today it agreed to sell its oncology business to Servier for $2.4 billion, in a deal that advances the buyer’s goal of expanding in cancer treatments—and has led to conflicting speculation about whether Shire would accept a takeover offer from would-be suitor Takeda Pharmaceutical should such a bid emerge later this month.Shire's oncology business includes two marketed treatments: Oncaspar ® (pegaspargase), a component of multi-agent treatment for acute lymphoblastic l